AU2017380583A1 - Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases - Google Patents

Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases Download PDF

Info

Publication number
AU2017380583A1
AU2017380583A1 AU2017380583A AU2017380583A AU2017380583A1 AU 2017380583 A1 AU2017380583 A1 AU 2017380583A1 AU 2017380583 A AU2017380583 A AU 2017380583A AU 2017380583 A AU2017380583 A AU 2017380583A AU 2017380583 A1 AU2017380583 A1 AU 2017380583A1
Authority
AU
Australia
Prior art keywords
compound
disease
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017380583A
Other languages
English (en)
Inventor
Pontus FORSELL
Gunnar Nordvall
Johan Sandin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzecure Pharma AB
Original Assignee
Alzecure Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzecure Pharma AB filed Critical Alzecure Pharma AB
Publication of AU2017380583A1 publication Critical patent/AU2017380583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017380583A 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases Abandoned AU2017380583A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1651706-2 2016-12-21
SE1651706 2016-12-21
PCT/GB2017/053868 WO2018115891A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
AU2017380583A1 true AU2017380583A1 (en) 2019-06-27

Family

ID=60923799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017380583A Abandoned AU2017380583A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Country Status (12)

Country Link
US (1) US20200113910A1 (https=)
EP (1) EP3558320A1 (https=)
JP (1) JP2020502225A (https=)
KR (1) KR20190098982A (https=)
CN (1) CN110167558A (https=)
AU (1) AU2017380583A1 (https=)
BR (1) BR112019012709A2 (https=)
CA (1) CA3046289A1 (https=)
IL (1) IL267086A (https=)
MX (1) MX2019007606A (https=)
RU (1) RU2019120431A (https=)
WO (1) WO2018115891A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52415A (fr) 2018-02-26 2021-01-06 AlzeCure Pharma AB Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
KR101457027B1 (ko) * 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
CN103180297A (zh) * 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Also Published As

Publication number Publication date
CN110167558A (zh) 2019-08-23
IL267086A (en) 2019-08-29
RU2019120431A (ru) 2021-01-22
BR112019012709A2 (pt) 2019-11-26
JP2020502225A (ja) 2020-01-23
RU2019120431A3 (https=) 2021-03-09
CA3046289A1 (en) 2018-06-28
WO2018115891A1 (en) 2018-06-28
EP3558320A1 (en) 2019-10-30
US20200113910A1 (en) 2020-04-16
MX2019007606A (es) 2020-07-29
KR20190098982A (ko) 2019-08-23

Similar Documents

Publication Publication Date Title
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
US20200113910A1 (en) Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
KR102387615B1 (ko) 단백질질환의 치료를 위한 벤질리덴구아니딘 유도체들의 신규한 치료적 용도
CN105189452A (zh) 苯基亚甲基胍衍生物以及其用于蛋白质错误折叠疾病的治疗用途
EP3814335B1 (en) 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
US20220324819A1 (en) Triazine derivatives for treating diseases relating to neurotrophins
US20210261513A1 (en) 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
JP2026067907A (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period